

**June 04, 2025**

**BSE Limited**

Department of Corporate Relationship  
1<sup>st</sup> Floor, New Trade Ring, Rotunda Building  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
*Scrip Code: 524742*

**National Stock Exchange of India Ltd.,**

Department of Corporate Services  
Exchange Plaza, 5<sup>th</sup> Floor,  
C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
*Scrip Code: CAPLIPOINT.*

Dear Sir/Madam,

**Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') - Investment in Triwin Pharma S.A DE C.V Mexico**

Pursuant to Regulation 30 of the SEBI Listing Regulations, we would like to inform that the Company's wholly owned Subsidiary Caplin Point Far East Limited, Hong Kong, had executed Share Purchase Agreement dated June 03, 2025 for acquiring the entire stake in Triwin Pharma S.A DE C.V, a Mexican Company.

The details required under regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure A.

Kindly take the same on record.

Thanking You,

Sincerely Yours  
**For Caplin Point Laboratories Limited**

**Venkatram G**  
**General Counsel & Company Secretary**  
**Membership No. A23989**

Encl: A/a

**Annexure – A**

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc	<p><b>Name of the Target entity:</b> Triwin Pharma S.A DE C.V</p> <p>The current share capital of the Company comprises of 50,000 equity shares of One Mexican Peso each. The turnover of the Company as on 31st March, 2025 was “nil”.</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length	<p>The target entity will be a related party of the Company and other subsidiaries once the acquisition is complete.</p> <p>Except the above, the Promoter/ promoter group/ group companies does not have any interest in the transaction.</p>
3.	Industry to which the entity being acquired belongs	Marketing and Distribution of Pharmaceutical products.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The target entity shall be the front-end entity for Caplin Point Laboratories Limited in the Mexican market for tender sales, direct sales, marketing and distribution of the products manufactured by Caplin Point Laboratories Limited and its subsidiaries.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No specific prior approvals are required for the acquisition.
6.	Indicative time period for completion of the acquisition	Share Purchase Agreement (SPA) to acquire the target company has been executed on June 03, 2025 and the acquisition of the target company will be completed once the consideration is paid by Caplin Point Far East Limited within 30 days from the date of signing the SPA.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	The entire consideration will be paid by Caplin Point Far East Limited through normal banking channels.
8.	Cost of acquisition and/or the price at which the shares are acquired	The shares shall be acquired at the face value of One Mexican Peso per share.

9.	Percentage of shareholding / control acquired and / or number of shares acquired	The entire share capital of target entity shall be acquired by Caplin Point Far East Limited thereby making it a wholly owned Subsidiary of Caplin Point Far East Limited and a step down subsidiary of the Company.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>The target entity's object is to operate in Mexico in the Pharmaceutical Marketing and Distribution business. Target entity was incorporated on 12<sup>th</sup> February, 2019 and it has reported no turnover in the past three years.</p> <p>The acquisition was a strategic decision, as it provides a local partner in Mexico—enabling participation in government tenders and also supporting the establishment of a stock-and-sale model, in line with our successful strategy in other LATAM markets.</p>

**For Caplin Point Laboratories Limited**

**Venkatram G**  
**General Counsel & Company Secretary**  
**Membership No. A23989**